FDAnews
www.fdanews.com/articles/145904-salix-progenics-announce-fda-extension-of-relistor-snda-goal-date

Salix, Progenics Announce FDA Extension of Relistor sNDA Goal Date

April 25, 2012
Salix Pharmaceuticals and Progenics Pharmaceuticals announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) action goal date for the agency’s review of the sNDA for Relistor (methylnaltrexone bromide) injection for subcutaneous use for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
MarketWatch